Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.
The pharmacokinetics of cefroxadine, a new orally active broad-spectrum cephalosporin, was studied in healthy volunteers and patients with impaired renal function after a single oral dose of 500 mg. The pharmacokinetic parameters of cefroxadine were obtained by analysing the serum level data of the drug based on a one-compartment open model. The mean serum half-life of cefroxadine was 0.97 h in healthy subjects, and was prolonged to 41.7 h in patients with a creatinine clearance of less than 5 ml/min. There was a significant linear correlation (p less than 0.001) between the elimination rate constant of the drug and the creatinine clearance. In healthy subjects, 71% of the administered dose was excreted in the urine collected over the first 6 h.
D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000378:metabolism*; D002515:Cephradine / Q000031:analogs & derivatives / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008875:Middle Aged
D002511:Cephalosporins; D003404:Creatinine; C012671:cefroxadine; D002515:Cephradine